title: Value of open-lung biopsy in 87 immunocompromised patients with pulmonary infiltrates.
abstract: The authors performed a retrospective analysis of 87 consecutive immunocompromised patients who underwent open-lung biopsy at the University of Utah Medical Center, Salt Lake City, Utah, from January 1971 to June 1982. A specific histologic diagnosis was obtained in 62 (71%) of the patients, 33 of whom had infections. Pneumocystis carinii was the most common microbial pathogen (16 patients), but no cases have been observed since 1980 when the routine use of prophylactic trimethoprim/sulfa began. The other specific diagnoses included malignancy or drug-induced lung disease. Specific therapy was available for 52 patients, and in 33 cases, a change in therapy was necessary to treat according to the lung biopsy diagnosis. Forty-one patients received an adequate course of therapy and 27 (66%) of these improved clinically, including 16 of 26 patients with infections, 11 of 14 with malignancies, and 1 of 2 with a vasculitis. Among the subgroup of 33 patients for whom a new, specific therapeutic option was available as a result of the biopsy diagnosis 21 (64%) responded to the treatment. Eleven significant operative complications were encountered, but no deaths were attributable to the biopsy. An open-lung biopsy in immunocompromised patients is a relatively safe, accurate diagnostic procedure which frequently facilitates appropriate therapy and clinical improvement.
authors.forename: B D
authors.initials: BD
authors.lastname: Cheson
authors.forename: W E
authors.initials: WE
authors.lastname: Samlowski
authors.forename: T T
authors.initials: TT
authors.lastname: Tang
authors.forename: S L
authors.initials: SL
authors.lastname: Spruance
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001706:Biopsy / Q000009:adverse effects / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000473:pathology; D005260:Female; D006801:Humans; D007154:Immune System Diseases / Q000150:complications*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007239:Infections / Q000473:pathology; D007938:Leukemia / Q000150:complications; D008168:Lung / Q000473:pathology*; D008171:Lung Diseases / Q000139:chemically induced / Q000209:etiology / Q000473:pathology*; D008172:Lung Diseases, Fungal / Q000473:pathology; D008175:Lung Neoplasms / Q000473:pathology; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D011020:Pneumonia, Pneumocystis / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents